Cargando…

Combining a CDK4/6 Inhibitor With Pemetrexed Inhibits Cell Proliferation and Metastasis in Human Lung Adenocarcinoma

BACKGROUND: Recent clinical trials of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in human lung adenocarcinoma (LUAD) have not achieved satisfactory results. The disappointing results of single-drug treatments have prompted studies about synergistic therapies of CDK4/6i with other drugs. We aim...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ke, Yuan, Liao, Cheng-Gong, Zhao, Zheng-Qing, Li, Xiao-Min, Lin, Rong-Jie, Yang, Long, Zhang, He-Long, Kong, Ling-Min
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9172583/ https://www.ncbi.nlm.nih.gov/pubmed/35686110 http://dx.doi.org/10.3389/fonc.2022.880153

Ejemplares similares

Survival Benefit and Genetic Profile of Pemetrexed as Initial Chemotherapy in Selected Chinese Patients With Advanced Lung Adenocarcinoma
por: Guo, Long-Hua, et al.
Publicado: (2020)

CDK 4/6 inhibitors for the treatment of meningioma
por: Young, Jacob S., et al.
Publicado: (2022)

CDK6 Immunophenotype Implicates Potential Therapeutic Application of CDK4/6 Inhibitors in Urothelial Carcinoma
por: Sun, Ran, et al.
Publicado: (2022)

Clinical efficacy and safety evaluation of pemetrexed combined with radiotherapy in treatment of patients with lung adenocarcinoma brain metastasis
por: Zhang, Guoqiao, et al.
Publicado: (2019)

Decitabine Sensitizes the Radioresistant Lung Adenocarcinoma to Pemetrexed Through Upregulation of Folate Receptor Alpha
por: Wang, Yuqing, et al.
Publicado: (2021)

Mechanisms and Implications of CDK4/6 Inhibitors for the Treatment of NSCLC
por: Zhang, Jinmeng, et al.
Publicado: (2021)

CDK4/6 inhibitor resistance: A bibliometric analysis
por: Pang, Jiayuecheng, et al.
Publicado: (2022)

CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors
por: Schettini, Francesco, et al.
Publicado: (2018)

Clinical and Pharmacologic Differences of CDK4/6 Inhibitors in Breast Cancer
por: George, Mridula A., et al.
Publicado: (2021)

Overexpression of miRNA-3613-3p Enhances the Sensitivity of Triple Negative Breast Cancer to CDK4/6 Inhibitor Palbociclib
por: Yu, Yuanhang, et al.
Publicado: (2020)

CDK4/6 Inhibitors in Combination Therapies: Better in Company Than Alone: A Mini Review
por: Rampioni Vinciguerra, Gian Luca, et al.
Publicado: (2022)

Pemetrexed Induced Life-threatening Anaphylaxis
por: Rajasurya, Venkat, et al.
Publicado: (2019)

Rationale for combination of paclitaxel and CDK4/6 inhibitor in ovarian cancer therapy — non-mitotic mechanisms of paclitaxel
por: Smith, Elizabeth R., et al.
Publicado: (2022)

Mechanisms of Resistance to CDK4/6 Inhibitors: Potential Implications and Biomarkers for Clinical Practice
por: McCartney, Amelia, et al.
Publicado: (2019)

CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells
por: Digiacomo, Graziana, et al.
Publicado: (2022)

Monoacylglycerol Lipase Knockdown Inhibits Cell Proliferation and Metastasis in Lung Adenocarcinoma
por: Zhang, Hao, et al.
Publicado: (2020)

CDK4/6 Inhibitor PD0332991 in Glioblastoma Treatment: Does It Have a Future?
por: Schröder, Lisette B. W., et al.
Publicado: (2015)

In vivo efficacy assessment of the CDK4/6 inhibitor palbociclib and the PLK1 inhibitor volasertib in human chordoma xenografts
por: Passeri, Thibault, et al.
Publicado: (2022)

Circular RNA ERBIN Promotes Proliferation of Hepatocellular Carcinoma via the miR-1263/CDK6 Axis
por: Yang, Shikun, et al.
Publicado: (2022)

Simultaneous Combination of the CDK4/6 Inhibitor Palbociclib With Regorafenib Induces Enhanced Anti-tumor Effects in Hepatocarcinoma Cell Lines
por: Digiacomo, Graziana, et al.
Publicado: (2020)

CDK7 Inhibitor THZ1 Induces the Cell Apoptosis of B-Cell Acute Lymphocytic Leukemia by Perturbing Cellular Metabolism
por: Abudureheman, Tuersunayi, et al.
Publicado: (2021)

Prognostic and immunological characteristics of CDK1 in lung adenocarcinoma: A systematic analysis
por: Du, Qingwu, et al.
Publicado: (2023)

Chemotherapy in Metastatic NSCLC – New Regimens (Pemetrexed, Nab-Paclitaxel)
por: Blais, Normand, et al.
Publicado: (2014)

PA28α/β Promote Breast Cancer Cell Invasion and Metastasis via Down-Regulation of CDK15
por: Li, Shengnan, et al.
Publicado: (2019)

Efficacy and safety of pemetrexed and nedaplatin followed by pemetrexed maintenance therapy in advanced lung adenocarcinoma
por: Lin, Zhong, et al.
Publicado: (2017)

Erratum: Chemotherapy in Metastatic NSCLC – New Regimens (Pemetrexed, Nab-Paclitaxel)
Publicado: (2014)

Significance of thymidylate synthase expression for resistance to pemetrexed in pulmonary adenocarcinoma
por: YANG, MIN, et al.
Publicado: (2014)

Targeting WEE1 Inhibits Growth of Breast Cancer Cells That Are Resistant to Endocrine Therapy and CDK4/6 Inhibitors
por: Fallah, Yassi, et al.
Publicado: (2021)

GZ17-6.02 and Pemetrexed Interact to Kill Osimertinib-Resistant NSCLC Cells That Express Mutant ERBB1 Proteins
por: Booth, Laurence, et al.
Publicado: (2021)

Prognostic Factors and Clinical Characteristics of Duodenal Adenocarcinoma With Survival: A Retrospective Study
por: Sun, Huapeng, et al.
Publicado: (2021)

Case report: (18)F-FES PET/CT predicted treatment responses of second-line and third-line CDK4/6 inhibitors after disease progression on first-line CDK4/6 inhibitor in a HR+/HER2- metastatic breast cancer patient
por: Pan, Bo, et al.
Publicado: (2022)

Efficacy and safety of hepatic artery infusion chemotherapy combined with tyrosine kinase inhibitors plus programmed death-1 inhibitors for hepatocellular carcinoma refractory to transarterial chemoembolization
por: Lin, Long-Wang, et al.
Publicado: (2023)

RBM10 Regulates Tumor Apoptosis, Proliferation, and Metastasis
por: Cao, Yingshu, et al.
Publicado: (2021)

MDM2 as a Rational Target for Intervention in CDK4/6 Inhibitor Resistant, Hormone Receptor Positive Breast Cancer
por: Portman, Neil, et al.
Publicado: (2021)

Editorial: Inhibitors of CDK family: New perspective and rationale for drug combination in preclinical models of solid tumors
por: Cavazzoni, Andrea, et al.
Publicado: (2023)

Interaction of KLF6 and Sp1 regulates basigin-2 expression mediated proliferation, invasion and metastasis in hepatocellular carcinoma
por: Kong, Ling-Min, et al.
Publicado: (2016)

NOL6 Regulates the Proliferation and Apoptosis of Gastric Cancer Cells via Regulating TP53I3, CDK4 and MCM7 Expression
por: He, Lei, et al.
Publicado: (2022)

A Protracted Course of COVID19 Infection in a Metastatic Breast Cancer Patient During CDK4/6 Inhibitor Therapy
por: Grinshpun, Albert, et al.
Publicado: (2020)

Combining Clinicopathological Parameters and Molecular Indicators to Predict Lymph Node Metastasis in Endometrioid Type Endometrial Adenocarcinoma
por: Jiang, Peng, et al.
Publicado: (2021)

Tumor Endothelial Marker 8 Promotes Proliferation and Metastasis via the Wnt/β-Catenin Signaling Pathway in Lung Adenocarcinoma
por: Ding, Chen, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_mrjp1hpddvfdefemgcdpqc62q6